Back to News
Jun 5, 2026 8:00 AM

Sanofi-Owkin Expand AI Collaboration With New Agentic AI Initiative

Owkin and Sanofi SA (NASDAQ:SNY) on Friday announced they have expanded their partnership through a new multi-year collaboration focused on developing next-generation AI-powered biopharma agents to support drug discovery and development.

The agreement also includes a five-year license for Owkin's AI Scientist platform, K Pro, marking the latest phase in a relationship that began in 2021.

Partnership Builds On Existing AI Research Efforts

The companies first teamed up through a 90 million euro strategic partnership centered on oncology target identification and patient subgroup analysis.

Read Also:

Microsoft Bets Big On Healthcare AI, Teams Up With Mayo Clinic

The collaboration was later broadened to support drug positioning efforts within Sanofi's immunology pipeline.

The newly announced initiative represents a deeper integration of AI into pharmaceutical ...